Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 10Observational 6Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Neoplasms 11Multiple Myeloma 10Recurrence 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 6Neuroblastoma 6Melanoma 6Leukemia, Myeloid, Acute 6Sarcoma 5Hematologic Neoplasms 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neurofibromatoses × 1 year × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡